Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | VDR | P11473 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8484861 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4815560 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL3545668 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL8483813 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4812770 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL11050599 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4951882 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL890725 | 0.98 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL483847 | 0.94 | ALDH1A1 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4193998 | 0.93 | RECQL (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023161645-A2 | PHARMACEUTICAL COMPOSITIONS FOR VAPORIZATION AND INHALATION | GROW BIOTECH PLC (GB) | 2023-08-31 | — | — | WO | claimed |
| US-20240115715-A1 | PHARMACEUTICAL COMPOSITIONS FOR VAPORIZATION AND INHALATION | GROW BIOTECH PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| WO-2023161645-A2 | PHARMACEUTICAL COMPOSITIONS FOR VAPORIZATION AND INHALATION | GROW BIOTECH PLC (GB) | 2023-08-31 | — | — | WO | disclosed |
| US-20080146768-A1 | PROCESSES FOR PREPARING POLYMERS USING ALPHA,OMEGA-DIFUNCTIONAL ALDARAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-23 | — | — | US | disclosed |
| EP-1083894-A1 | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999063994-A9 | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999063994-A1 | MULTIBINDING INHIBITORS OF HMG-CoA REDUCTASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-5886007-A | USEFUL TO TREAT ALZHEIMER'S DISEASE WITH REDUCED SIDE EFFECT | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1999-03-23 | — | — | US | disclosed |
| US-5783584-A | USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 1998-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | ALOX5, GSTO1, FASN | ALDH1A1 40/4885CYP3A4 871/4885CYP2C9 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.